
Overview
4cell Therapies is a company that develops CAR-T therapies for treating solid tumors, including challenging cases like pancreatic cancer, and hematological cancers such as leukemia and lymphoma. The company conducts research and development in Poland, utilizing advanced genetic engineering to create antigen receptors that target and destroy cancer cells. They also optimize production processes to meet GMP standards, ensuring scalability for future commercialization.
Financials
Revenue history (in k)
Financial insight
- The statement flags a going concern risk. Sprawozdanie finansowe zostało sporządzone przy założeniu kontynuacji działalności w dającej się przewidzieć przyszłości tj. w szczególności przez okres co najmniej 12 miesięcy od dnia bilansowego mimo, że Spółka poniosła w bieżącym okresie stratę netto w wysokości minus 2 726 951,55 zł, co zwiększyło straty lat ubiegłych. Na dzień podpisania sprawozdania finansowego Zarząd zauważa występowanie niepewności co do możliwości kontynuowania działalności na skutek braku środków finansowych, w porównaniu do potrzeb na najbliższy rok obrotowy, trwający od stycznia 2026 do grudnia 2026. Zarząd podejmuje działania opisane w nocie 38 do sprawozdania finansowego, co uzasadnia przyjęcie założenia kontynowania działalności.
Filing timeliness
Financial statements were filed on time, on average 23 days early. All were audited by a statutory auditor.
- 202513/07/2026
- 202408/07/2025
- 202312/07/2024
- 202213/02/2023
- 202125/01/2022
- 202002/02/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Industry
Authorized Representatives
Manner of representation
1. The submission of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy. 2. If the management board is a one-person management board, one member of the management board is authorized to submit declarations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2013-02-07.
02 1750 1211 0000 0000 3066 1052
55 1750 1211 0000 0000 3066 1068
17 1600 1462 1087 3348 5000 0001
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-03-01 | Development of a new, effective and highly specific breast cancer therapy with potentially low toxicity, based on the patented DOS47 technology platform, which modifies the tumor microenvironment and immune response by changing pH. | $3.2M$3,171,859 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Onconick sp. z o.o. | $39,587.95 | onconick.com | ||
| Biolabic sp. z o.o. | $37,688.85 | biolabic.pl | ||
| Cannamedai S.A. | $28,203.90 | cannamedai.com | ||
| DR Joanna Sanford sp. k. | $28,674.82 | sanfordbiotech.com | ||
| Inventro S.A. | $25,971.59 | inventro.co | ||
| Cellis sp. z o.o. | $24,935.59 | cellis.eu | ||
| Nanovelos S.A. | $24,842.03 | nanovelos.com | ||
| Oncotherics Poland S.A. | $7,565.33 | oncotherics.com | ||
| Bioinfo Capital sp. z o.o. | $7,450.04 | bioinfo.pl | ||
| Synerga.Fund S.A. | $3,772.65 | synergafund.com.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-10 | Share capital increase (2,520,815.60 PLN → 3,172,432.10 PLN) | |
| 2026-05-15 | Share capital increase (2,065,653.70 PLN → 2,520,815.60 PLN) | |
| 2023-12-27 | Share capital increase (1,880,468.50 PLN → 2,065,653.70 PLN) | |
| 2021-06-07 | Name change (Helix Immuno-Oncology → 4cell Therapies) | |
| 2020-10-27 | Share capital increase (1,321,950.00 PLN → 1,880,468.50 PLN) |
FAQ
Last updated: 2026-09-10